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Abstract
Ischemia-reperfusion injury (IRI) is a leading cause of AKI. This common clinical complication lacks
effective therapies and can lead to the development of CKD. The αvβ5 integrin may have an important role
in acute injury, including septic shock and acute lung injury. To examine its function in AKI, we utilized a
specific function-blocking antibody to inhibit αvβ5 in a rat model of renal IRI. Pretreatment with this anti-
αvβ5 antibody significantly reduced serum creatinine levels, diminished renal damage detected by
histopathologic evaluation, and decreased levels of injury biomarkers. Notably, therapeutic treatment with
the αvβ5 antibody 8 hours after IRI also provided protection from injury. Global gene expression profiling
of post-ischemic kidneys showed that αvβ5 inhibition affected established injury markers and induced
pathway alterations previously shown to be protective. Intravital imaging of post-ischemic kidneys
revealed reduced vascular leak with αvβ5 antibody treatment. Immunostaining for αvβ5 in the kidney
detected evident expression in perivascular cells, with negligible expression in the endothelium. Studies in
a three-dimensional microfluidics system identified a pericyte-dependent role for αvβ5 in modulating
vascular leak. Additional studies showed αvβ5 functions in the adhesion and migration of kidney pericytes
in vitro. Initial studies monitoring renal blood flow after IRI did not find significant effects with αvβ5
inhibition; however, future studies should explore the contribution of vasomotor effects. These studies
identify a role for αvβ5 in modulating injury-induced renal vascular leak, possibly through effects on
pericyte adhesion and migration, and reveal αvβ5 inhibition as a promising therapeutic strategy for AKI.
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Ischemia-reperfusion injury (IRI) after surgical procedures is a common in-hospital event that can result in
AKI.  Originally thought to be a transient decrease in glomerular function, it is now clear that AKI
frequently does not fully resolve and can contribute to the progression of CKD.  As a result there is a high
rate of morbidity and mortality attributable to AKI.  Currently there is no pharmacologic therapy
specifically approved for AKI after IRI.
Renal tubular injury is a key pathophysiologic outcome of IRI, however, it is known that AKI is a complex
disorder resulting from inflammation and microvascular changes in addition to tubular injury.  Alterations
in microvascular function, such as abnormal coagulation, increased vascular tone, and increased vascular
permeability, promote inflammatory responses leading to continued ischemic conditions and further tissue
injury.  Increased microvascular permeability is thought to result from loss of the integrity of the
endothelium because of changes in the actin cytoskeleton and endothelial cell contacts.  Pericytes are also
critical to the maintenance of microvascular barrier integrity.  Mice lacking pericytes have increased
vascular permeability and the presence of pericytes has been shown to regulate permeability signaling and
suppress inflammation, leading to enhanced barrier function.  After acute injury, renal pericytes have been
shown to develop into myofibroblasts, contributing to the progression of CKD after AKI.  However, there
are no data directly implicating kidney pericytes in vascular leak associated with AKI.
Integrins comprise a large family of membrane receptors that bind extracellular matrix proteins as well as
other secreted proteins and membrane-tethered ligands. The RGD integrins are one class of integrins that
bind this motif (arginine-glycine-aspartic acid), found in several extracellular matrix proteins. Integrin αvβ5
is an RGD-binding integrin that binds to several extracellular ligands, including vitronectin  and milk fat
globule protein E8 (MFG-E8). αvβ5 has been reported to be expressed in multiple cell types in vitro,
including endothelial cells, epithelial cells, fibroblasts, and various leukocyte lineages.  A number of
biologic functions have been attributed to αvβ5, ranging from tumor angiogenesis  and phagocytosis  to
adenoviral uptake,  fatty acid uptake,  and retinal pigment epithelium homeostasis.
Several studies have also demonstrated a role of αvβ5 in regulating vascular barrier integrity. αvβ5-
deficient mice have attenuated VEGF-induced vascular leak in the brain and skin,  and have reduced
vascular leak in models of sepsis.  In addition, αvβ5-deficient mice or mice treated with an αvβ5 function-
blocking antibody have attenuated vascular leak in acute lung injury.  Mechanistically it has been shown
that αvβ5 inhibition could prevent stress fiber formation in response to stimuli (e.g., VEGF, IL1β, and LPS)
and subsequently attenuate endothelial cell permeability.
Given the role of αvβ5 in regulating vascular permeability and its previously described function in models
of acute injury, we sought to explore the role of αvβ5 in the pathogenesis of IRI-induced AKI. Here we
demonstrate that treatment with a function-blocking mAb specific for αvβ5 attenuates AKI in a rat model
of renal IRI. We further show that αvβ5 inhibition attenuates microvascular permeability in this model.
Analysis of αvβ5 immunostaining reveals expression in perivascular cells of the kidney, including vascular
smooth muscle cells (VSMCs) and pericytes. We demonstrate that blocking αvβ5 can attenuate vascular
leak in a three-dimensional microfluidic coculture system in a pericyte-dependent manner. Our data support
a novel mechanism for αvβ5 in mediating vascular permeability in AKI.
Results
Inhibition of αvβ5 Integrin Reduces Renal Injury after IRI
A rat model of renal IRI was used to investigate the role of αvβ5 integrin in AKI. Rats were treated with
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two doses of a function-blocking αvβ5 antibody (ALULA, previously described by Su et al. ), 18 hours
preclamp and 30 hours post-ischemia. IRI produced a marked increase in serum creatinine in the control
antibody-treated rats that was significantly reduced in the αvβ5 antibody-treated rats (Figure 1A). Because
no significant differences among the 10, 3, and 1 mg/kg doses of αvβ5 antibody were detected, further
experiments were conducted with lower doses of antibody and under these conditions a dose-response was
observed (Figure 1B).
A single dose of αvβ5 antibody administered 6 hours preclamp also significantly reduced serum creatinine
levels at 24, 48, and 72 hours postinjury (Figure 2A). Effects of this single antibody dose were further
evaluated using histopathologic end points. Composite lesion scores combining features of injury and
regeneration were assessed by stereological analysis of hematoxylin and eosin–stained kidney sections.
These correlated well with the serum creatinine results, with significant inhibition of lesions in the αvβ5
antibody group observed at 72 hours post-ischemia (Figure 2B).
A major consequence of renal ischemia is tubular epithelial cell death.  Activated caspase-3 was used as a
marker of cell death in kidney to investigate whether αvβ5 inhibition modulates ischemia-induced epithelial
cell loss. Activated caspase-3 levels in the renal medulla were found to be significantly reduced at 24 hours
in the kidneys of αvβ5 mAb-treated rats (Figure 3). The levels of additional injury markers α-smooth
muscle actin and PDGFRβ were also substantially reduced 72 hours post-ischemia with αvβ5 inhibition,
further supporting the protective effect of αvβ5 inhibition during IRI (Supplemental Figures 1 and 2).
Expression Profiling Reveals Biomarkers of Renal Injury Are Decreased with αvβ5
Blockade
To evaluate the effects of αvβ5 inhibition on translatable biomarkers, we tested urine and serum collected
post-IRI with the proteomic Rat KidneyMAP to evaluate the presence of proteins associated with renal
injury. We identified two well established biomarkers, urinary KIM-1 and serum MCP-1 (Supplemental
Figure 3), that exhibited patterns consistent with the biochemical and histologic indicators showing
decreased injury with αvβ5 antibody treatment.
Microarray analysis was performed on kidneys from control and αvβ5 mAb-treated rats at 24 and 72 hours
post-IRI, to explore the impact of αvβ5 inhibition on global gene expression. Blockade of αvβ5 resulted in
1460 and 604 transcripts differentially regulated at 24 and 72 hours compared with control antibody
treatment, respectively. The differential expression of a subset of these genes was confirmed by quantitative
PCR (Supplemental Table 1). Ingenuity Pathway Analysis revealed several biologic pathways impacted by
αvβ5 inhibition, including increased migration/differentiation of endothelial cells and increased
proliferation of kidney cells with a concomitant decrease in immune cell recruitment and renal epithelial
cell death (Table 1). In addition, markers of ischemic injury previously described in either rodent models of
AKI or in human AKI, including KIM-1 (havcr1), Ngal (lcn2), and uromodulin (umod), were also altered
by αvβ5 inhibition (Figure 4). Ingenuity Upstream Regulator Analysis evaluated this gene expression
dataset and predicted the inhibition of three signaling pathways involved in vascular permeability (IL1β,
thrombin, and VEGF) as possible αvβ5-mediated molecular mechanisms in IRI (Supplemental Figure 4).
Integrin αvβ5 Modulates Injury-Induced Vascular Permeability
The described role for αvβ5 in vascular leak led us to examine the ability of αvβ5 antibody treatment to
attenuate vascular permeability after IRI. Intravital imaging was performed in rats 24 hours post-IRI using
a rhodamine-conjugated albumin and a high molecular weight dextran to evaluate the microvascular
permeability over time. We observed leakage of both the albumin and dextran from the renal
microvasculature in the control antibody-treated animals. Leakage of both markers was also observed in the
αvβ5 mAb-treated animals. However, the extent of leakage in the αvβ5 mAb-treated animals was
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significantly less than that observed in the control antibody-treated animals (Figure 5).
In an effort to understand whether changes in renal blood flow would also contribute to the protection
observed from αvβ5 antibody treatment, we conducted additional intravital microscopy to evaluate red
blood cell (RBC) flow rates. At 24 hours post-IRI there was no significant difference in RBC flow rates
between control and αvβ5 antibody-treated animals (Supplemental Figure 5), indicating that αvβ5
inhibition does not alter cortical blood flow in IRI at this time point. This study does not rule out the
possibility that αvβ5 inhibition is altering blood flow at an earlier time point or altering flow in the outer
medulla. Future studies should comprehensively address the possibility of αvβ5-mediated changes in blood
flow and its contribution to the protection from vascular leak and injury observed with αvβ5 antibody
treatment.
Integrin αvβ5 Expression in the Kidney
Previous studies report expression of αvβ5 in multiple cell types in vitro ; however, there has not been
an evaluation of the expression pattern in the kidney in vivo. To address the localization of αvβ5 in the
kidney, we generated an affinity-purified rabbit polyclonal antibody that could detect integrin β5 in
formalin-fixed paraffin-embedded tissue. Staining mouse kidneys with this antibody revealed broad
expression of αvβ5 in multiple regions of the kidney, including the glomerulus and cortical interstitium, and
specificity of the staining was confirmed using β5 null mouse tissue and competition with soluble αvβ5
protein (Supplemental Figure 6, B and C).
To assess if αvβ5 is present in renal perivascular and endothelial cells, we conducted immunofluorescence
for αvβ5, PDGFRβ, and CD31 on frozen tissue sections from mouse (Figure 6) and rat (Supplemental
Figure 7). Our analysis suggests αvβ5 is generally present on PDGFRβ-expressing cells and is largely
absent from CD31-expessing endothelial cells (Figure 6). The PDGFRβ immunostaining also colocalized
with NG2 (a proteoglycan expressed on pericytes and VSMCs), providing further evidence for αvβ5
expression in perivascular cells (Supplemental Figure 8).
To identify any changes that injury may induce in the expression or localization of αvβ5, we
immunostained rat kidneys 24 hours post-IRI. No substantial changes were detected in the levels of αvβ5
expression or in its localization pattern post-IRI compared with an uninjured kidney (Supplemental Figure
7).
Integrin αvβ5 Attenuates Vascular Leak in a Pericyte-Dependent Manner
To evaluate αvβ5 antibody treatment in human kidney cells, we performed three-dimensional vascular
permeability assays. Human renal endothelial cells were cultured in two different conditions: in the absence
and presence of human kidney pericytes in a three-dimensional microfluidic device. As expected, treatment
of the microvessels with thrombin significantly increased vascular permeability (P ) in both the absence
and presence of pericytes. Treatment with the αvβ5 antibody had no significant effect on thrombin-induced
permeability in endothelial cells alone (Figure 7A) but had a profound inhibitory effect on vascular leak in
the coculture system (Figure 7B).
Quantitative PCR on cells from the microfluidic devices revealed substantially higher levels of itgb5
mRNA in the kidney pericytes and in the coculture compared with endothelial cells alone, indicating that
β5 integrin expression is very low or absent in endothelial cells (Supplemental Figure 9).
Additional permeability studies were performed with LPS to demonstrate a broad role for αvβ5 in
regulating vascular permeability. As with thrombin, αvβ5 inhibition also significantly inhibited LPS-
induced permeability (Supplemental Figure 10A). F-actin staining in these devices revealed LPS treatment
induces cytoskeletal disorganization, whereas normal cytoskeletal arrangements are largely preserved with
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αvβ5 inhibition (Supplemental Figure 10B). These results suggest that αvβ5 regulates vascular permeability
in a pericyte-dependent manner.
Integrin αvβ5 Is Important for Pericyte Adhesion and Migration
Integrins, including αvβ5, have a well defined role in regulating adhesion and migration in numerous cell
types, and these processes could contribute to the function of pericytes in response to injury. To examine
the contribution of αvβ5 to pericyte adhesion we plated human kidney pericytes on either vitronectin (a
known αvβ5 ligand) or collagen (not an αvβ5 ligand) in the presence or absence of antibody treatment. The
αvβ5 mAb led to a nearly 90% reduction in cell adhesion to vitronectin, but had no significant impact on
adhesion to collagen (Figure 8A).
Migration studies were also performed using a scratch wound assay on human kidney pericytes on either
collagen or vitronectin. Antibody treatment did not impact migration on collagen; however, on vitronectin,
αvβ5 antibody treatment significantly inhibited pericyte migration (Figure 8B). These studies demonstrate a
ligand-dependent function for αvβ5 in pericyte adhesion and migration, properties which are likely to
contribute to the αvβ5-dependent function of pericytes in vascular permeability.
Postclamp Treatment with αvβ5 Antibody Attenuates Injury Response
In order to evaluate the translational capacity of αvβ5 inhibition, we employed a therapeutic dosing
strategy. Rats were administered αvβ5 antibody 8 hours postclamp release. This single therapeutic dose
significantly reduced serum creatinine levels at 48 hours postinjury (Figure 9A). The effects of this dosing
strategy were further evaluated using quantitative PCR of AKI biomarkers in kidneys isolated 72 hours
post-IRI. αvβ5 inhibition significantly reduced the expression of two biomarkers induced by injury (havcr1,
lcn2) and increased the expression of two biomarkers diminished by injury (umod, egf). Together, these
data demonstrate that treatment even several hours after ischemia may have therapeutic benefit.
Discussion
Here, we have shown that inhibition of integrin αvβ5, with a selective mAb, attenuates AKI in an IRI rat
model. We further show that this antibody reduces vascular permeability, suggesting a mechanistic role for
αvβ5 in the pathogenesis of AKI. Importantly, we show that αvβ5 is predominantly expressed in
perivascular cells in the kidney, including pericytes. Using a novel three-dimensional microfluidic culture
system we demonstrate for the first time a role for αvβ5 function in pericytes leading to regulation of
vascular leak. Importantly, inhibition of αvβ5 hours after ischemia was still able to provide renal protection,
indicating that this antibody could be a promising therapy for AKI.
The demonstration that αvβ5 plays a key role in the kidney upon acute injury is consistent with previous
data in other tissues, including protection from cerebral ischemia in β5 null mice  and αvβ5 inhibition
resulting in reduced vascular leak in pulmonary ischemia.  Along with these in vivo studies, reports
indicate that αvβ5 is expressed in monolayer cultures of endothelial cells and that anti-αvβ5 antibody
treatment attenuates endothelial permeability.  In our studies, we evaluated the role of αvβ5 in
vascular leak using a three-dimensional microfluidic system that better mimics the in vivo structural and
physiologic environment of the intact microvasculature. In this system, we observed that αvβ5 does indeed
play a key role in modulating vascular leak, but that this effect is largely dependent on pericytes. The
reason for the experimental discrepancy between the three-dimensional system and the previous two-
dimensional endothelial culture systems is uncertain, but there are numerous examples of three-
dimensional culture systems better mimicking in vivo biology.  In addition to the three-dimensional
microenvironment, the system we used incorporates flow. It is well established that vascular flow is critical
for proper vascular barrier formation,  which is consistent with our observations that flow leads to a
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much tighter barrier than observed in a static culture system (data not shown). Furthermore, it has been
previously shown that pericytes are instrumental for proper vascular barrier function.  Likewise, in using
this three-dimensional system we observe an improved barrier in the presence of pericytes. Taken together,
this suggests that the three-dimensional system we have used more accurately recapitulates the biology of
the microvascular barrier.
Consistent with a pericyte-dependent role for αvβ5 in modulating vascular leak, we observe expression of
αvβ5 in perivascular cells of the kidney, including VSMCs and pericytes, whereas no detectable expression
was observed in endothelial cells. Similarly, stromal cell-restricted expression of αvβ5 in lung has also been
observed (data not shown). Consistent with our results, previous studies evaluating in situ expression of
αvβ5 in the kidney have reported predominant mesangial cell expression in the glomerulus.
Improved renal blood flow post-IRI is likely to have a protective effect on kidney function. The observed
expression of αvβ5 in VSMCs suggests there may be a mechanism whereby αvβ5 inhibition ameliorates
injury-induced vasoconstriction and improves blood flow. Our initial study using intravital microscopy to
evaluate RBC flow in renal cortical vasculature post-IRI did not detect a significant difference in blood
flow with αvβ5 inhibition. However, it is important to note that this study does not rule out the possibility
that αvβ5 inhibition is altering blood flow at an earlier time point or altering flow in the outer medulla.
Future studies that include a detailed time course analysis of blood flow throughout all phases of the injury
could reveal another novel function for αvβ5 and expand on the protective effects of αvβ5 antibody
treatment.
The in vivo immunostaining and ex vivo microfluidics studies suggest a role for αvβ5 in pericytes, which
are known to be critical for proper barrier function in the microvasculature.  This has been best studied in
brain microvasculature where it has been shown that the absence of pericytes leads to breakdown of the
blood–brain barrier.  In kidneys the role of pericytes in vascular leak has not been studied. In the context
of acute injury in the kidney, pericytes can differentiate into αSMA-positive myofibroblasts and play a key
role in contributing to the fibrotic response.  Recent work has shown that ablation of pericytes in the
kidney leads to a rapid AKI, peritubular capillary loss, and lethality,  supporting the role of pericytes in
maintaining normal kidney function. A key area of study will be to explore the precise cellular role of αvβ5
in pericytes that contribute to its role in AKI.
To begin to understand this we have evaluated some functions of αvβ5 in pericytes in vitro. We have shown
that αvβ5 is instrumental for pericyte adhesion as well as migration on a vitronectin substrate, a known
αvβ5 ligand. Vitronectin has been associated with the pathogenesis of several disease processes including
neointimal formation in blood vessels,  liver cirrhosis,  diabetic nephropathy,  and CKD.  This
involvement of vitronectin with disease states lends potential biologic significance to the regulation of
pericyte migration on this substrate.
It has been proposed that pericytes may migrate from endothelial cells after ischemic injury  and it is
plausible that this migration may contribute to the vascular permeability in renal IRI. In addition, pericyte
migration away from the vasculature is thought to result in their differentiation to myofibroblasts.  By
impairing the ability of pericytes to migrate, αvβ5 inhibition could maintain pericyte–endothelial
interactions, resulting in reduced vascular leak and diminished myofibroblast differentiation. This is
supported by the reduced myofibroblast expansion observed with αvβ5 inhibition. This suggests that αvβ5
antibody could potentially protect from longer-term damage like the renal fibrosis that occurs in the weeks
and months after AKI (reviewed in Ferenbach and Bonventre ).
Overall, our data highlight an important role for αvβ5 in the pathogenesis of AKI and suggests that
targeting this integrin to attenuate vascular permeability could provide an effective therapy, one that is
mechanistically highly differentiated from other therapeutic approaches that have failed in the clinic
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setting.
Concise Methods
Unilateral Clamp Ischemia Model
Animal experiments were approved by the Indiana University School of Medicine Institutional Animal
Care and Use Committee. Male Sprague Dawley rats (Harlan Laboratories) were anesthetized with
isoflurane and placed on a warming pad for temperature maintenance. The right kidney was removed and
the renal artery and vein sutured off. Ischemia of the left kidney was initiated by clamping the renal artery
and vein for 30 minutes using nontraumatic clamps (Fine Scientific Tools). At the conclusion of the
ischemic period, the clamps were removed and the kidneys were observed to insure rapid re-establishment
of blood flow. The αvβ5 blocking antibody (ALULA) used in these studies was previously described.  The
2H6 mouse IgG2b mAb was used as a control. Antibodies were administered at a volume of 300 μl by
subcutaneous injection at defined times before clamping.
Immunostaining of Fixed Kidneys
To detect αvβ5 in formalin-fixed, paraffin-embedded tissues, a human β5 integrin-specific polyclonal
antiserum was prepared by immunizing a rabbit with purified soluble human αvβ5 ectodomain protein
generated with recombinant constructs in CHO cells. The total IgG fraction was purified from the
antiserum using protein-A affinity chromatography, and subjected to affinity depletion using Sepharose
beads conjugated to soluble human αvβ6 protein, in order to remove human αv-reactive components. The
human β5-integrin specific rabbit antibodies were then affinity purified using Sepharose beads conjugated
to soluble human αvβ5 protein. The final isolated rabbit IgG fraction was only reactive to human β5-
containing integrin but not any other integrin subunits, as tested by ELISA (data not shown). Formalin-
fixed tissues were embedded in paraffin, sectioned at 5 µM, and processed on the Ventana Discovery XT
platform (Roche) using the purified anti-human β5 polyclonal antibody. Immunohistochemistry of
additional markers was performed as above, using the following antibodies: PDGFRβ (Thermo Fisher),
α-smooth muscle actin (αSMA; Abcam, Inc.), and activated caspase-3 (Cell Signaling Technology).
Quantification of caspase-3 immunoreactive area was accomplished by custom-designing algorithms in
Visiopharm (Denmark) software.
Additional immunostaining for αvβ5 was performed on frozen tissue from rat (Sprague–Dawley strain;
Harlan/ENVIGO) and mouse (Itgb5 β5 null strain and wild-type 129 SvJ strain; Jackson
Laboratories). Tissues were fixed in 4% PFA and embedded in OTC (Electron Microscopy Sciences).
Frozen blocks were sectioned on a cryostat at 10–20 µm thickness and slides were stored at −80°C.
Primary and secondary antibodies were as follows: αvβ5 antibody ALULA  (humanized variant), mouse
anti-rat CD31 or rat anti-mouse CD31 (eBioscience), rabbit anti-PDGFRb (clone 28E1; Cell Signaling
Technology), mouse anti-rat NG2 (Abcam, Inc.), anti-human Cy3 (Jackson ImmunoResearch), anti-rabbit
AF647, anti-rat AF488, and anti-mouse AF488 (Life Technologies). Images were acquired on a Marianas
confocal system (3i) at submicron z-axis resolution. Three-dimensional image stacks were pseudocolored
and reconstructed with Volocity (Perkin-Elmer).
Histologic Evaluation
Hematoxylin and eosin–stained sections from formalin-fixed, paraffin-embedded kidneys were examined
by a blinded, board certified veterinary pathologist for injury and regeneration using a scoring method
modified from Kelleher et al.  The following criteria were scored: (1) injury score: tubular necrosis,
calcific debris in tubular lumina, interstitial inflammation, casts, juxta-glomerular apparatus prominence,
interstitial edema, brush border loss, tubular proteinosis, and pelvic congestion; and (2) regeneration score:
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neutrophils in vasa recti, tubular regeneration, and tubular cell mitoses. Lesions were scored on a scale of
0–2 (0, none; 0.5, minimal; 1, mild; 1.5 moderate; and 2, marked). Composite lesion scores presented are a
combination of the injury and regeneration scores.
Serum and Urine Biomarker Measurements
Serum creatinine was measured at baseline and at days 1, 2, and 3 postclamp (animals euthanized at 24
hours postclamp have only baseline and day 1 serum creatinine measurements). Levels were measured
using an AU480 Chemistry Analyzer (Beckman) and reported as milligram per deciliter. Profiling of serum
and urine biomarkers of renal injury was conducted using the Luminex Bead assay platform with the
multianalyte panel Rat KidneyMAP v1.0 (Myriad RBM).
RNA Isolation, Microarray Analysis, and Quantitative PCR
Total RNA from the kidney was isolated in QIAzol (Qiagen) using mechanical disruption on the FastPrep
system (MP Biomedical), and purified using the RNeasy Mini Kit (Qiagen). RNA was quantitated
(NanoDrop; Thermo Fisher) and was evaluated for integrity using the RNA 6000 Nano Assay on a
Bioanalyzer 2100 (Agilent).
Gene expression microarray experiments were performed at Expression Analysis (a Quintiles company) as
follows. Total RNA was labeled and hybridized using the Ambion WT Expression kit according to the
manufacturer’s instructions. After hybridization, arrays were washed and stained using standard Affymetrix
procedures before scanning on the Affymetrix GeneChip Scanner. For differential expression analysis, a
two-group analysis was performed using the comparative method Permutation Analysis for Differential
Expression to develop false discovery rate-based estimates of groups of genes using a shrunken t-statistic.
A false discovery rate of <0.05 and a fold change of >1.5 (control antibody-treated versus αvβ5 antibody-
treated) was considered significant.
For quantitative PCR confirmation of microarray results, cDNA was synthesized from 1 µg of RNA using
the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher) and quantitative PCR was performed using
Taqman Gene Expression assays run on the QuantStudio 7 (Thermo Fisher). Ct values of target genes were
normalized to the eif1a control gene to generate ΔCt values.
Intravital Microscopy to Evaluate Vascular Permeability and RBC Flow In Vivo
Rat serum albumin was conjugated to Texas Red as previously described (TR-RSA).  A 150 kD
fluorescein conjugated dextran (TdB Consultancy) was dissolved in normal saline. To remove any small
molecular weight components, the stock solution was dialyzed against normal saline using a 100 kD
MWCO Spectra-Por Float-A-Lyzer membrane (Thermo Fisher).
Images were acquired using an Olympus FV-1000 microscope, with an original magnification of ×60,
1.2NA water immersion objective, and highly sensitive GaAsP nondescanned (external) detectors. Ten
random fields were marked and imaged at 5, 15, and 30 minutes postinfusion of the dual TR-RSA/150 kD
fluorescein dextran bolus. All of the images were taken approximately 5–10 μm below the kidney capsule
where interstitial space is prevalent.
The degree of extravasation of the two different molecular mass markers (approximately 66 kDa for the
TR-RSA and 150 kDa for the fluorescein-dextran) was used examine the severity of damage to vascular
integrity. TR-RSA was used to rank mild to moderate vascular damage and the 150 kD fluorescein-dextran
was used to rank more severe damage (see Supplemental Material for details). A score of 0 indicates that
no amount of the compound is present in the interstitial space. A score of 1 is given to an image where
some amount of the compound is seen in the interstitial space of a small region of the total image. A score
43
Inhibition of αvβ5 Integrin Attenuates Vascular Permeability and Protect... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461783/?report=printable
8 of 23 2/15/2019, 7:27 AM
of 2 is given to an image where the compound leaks into the interstitial space of the majority of the image.
A score of 3 is given to an image where the concentration of the compound in the interstitial space starts to
match the intensities seen in the circulating microvasculature. This is indicative of severe damage
particularly for TR-RSA at 5 and 15 minute time points or the 150 kD fluorescein-dextran at any time
point.
RBC velocity was calculated as previously described.  Briefly, utilizing the 150 kD dextran retained in the
vasculature, RBC velocity was determined from single plane images or line scans as the dextran labels only
the plasma and is excluded from RBC and white blood cells causing them to appear as dark streaks. This
was accomplished by determination of the slope induced during image acquisition of the RBCs; faster
moving RBC produce a shallower slope while slower moving RBCs produce a steeper slope. Speed was
calculated by using the dimensions of time (the y-axis) and distance (the x-axis).
Microfluidic Platform for Vascular Permeability
To determine the permeability of endothelial monolayers and endothelial-pericyte co-cultures in vitro,
microvessels were formed in microfluidic devices as described previously.  Human renal glomerular
endothelial cells (ScienCell) (and in specified cases, human renal pericytes) were seeded in 160 μm
diameter tubes formed in collagen type I hydrogels to create lumenized microvessels, and 70 kD dextran
was perfused through the vessel lumens to quantify the diffusive permeability.
In Vitro Pericyte Adhesion Assay
Costar 96-well high binding plates were coated overnight at 4°C with 0.1% collagen (Sigma) or 10 μg/ml
vitronectin in PBS (R&D Systems). Plates were washed then blocked for 1 hour at 37°C and washed with
buffer again. Antibodies (10 µg/ml) 2H6, anti-αVβ5, and anti-αVβ3 (MAB1976; Millipore) were added to
wells prior to cell seeding. Human fetal kidney pericytes were fluorescently labeled with Calcein-AM
(Molecular Probes) and seeded into antibody-containing wells. After incubation, plates were washed then
read on a Synergy H microplate reader (BioTek) to quantify adherent cells via fluorescent intensity.
Scratch Wound Migration Assay
Essen Bioscience 96-well ImageLock plates were coated overnight at 4°C with 0.1% collagen (Sigma) or
10 μg/ml vitronectin in PBS (R&D Systems), then washed with PBS. Human fetal kidney pericytes were
seeded in Opti-MEM (Thermo Fisher) and incubated at 37°C for 6 hours prior to scratch using the
Woundmaker (Essen Bioscience). Antibodies 2H6, anti-αVβ5, anti- αVβ3 (MAB1976; Millipore), or a JNK
inhibitor (Selleckchem SP600125) were added to the wells 1 hour before scratch. Plates were imaged in the
Incucyte ZOOM system (Essen Bioscience) every 2 hours for 48 hours. An analysis was run on each plate
and wound confluence was calculated at each individual time point for each treatment condition.
Statistical Analyses
GraphPad Prism 6 (GraphPad Inc.) was used to analyze the data. Data were analyzed by two-tailed t test or
two- or one-way ANOVA with post hoc analysis as appropriate. P<0.05 was used to indicate significance.
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Figure 1.
Treatment with αvβ5 mAb protects kidneys in a rat model of renal IRI. To establish the dose-response efficacy of an αvβ5-
blocking antibody (αvβ5 antibody), rats were treated with (A) 10, 3, or 1 mg/kg or (B) 3, 1, 0.3, or 0.1 mg/kg at 18 hours
pre- and 30 hours post-clamp. Doses of 10 and 3 mg/kg were equally effective in attenuating ischemia-induced serum
creatinine increases at 24, 48, and 72 hours post-injury. *P<0.05; **P<0.01 versus control antibody; error bars = SEM.
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Figure 2.
Single dose of αvβ5 antibody improves kidney function and reduces tubular injury. (A) Rats were treated with a single
dose (3 mg/kg) of αvβ5 antibody 6 hours before ischemic injury. This single dose was effective in attenuating ischemia-
induced serum creatinine increases at 24, 48, and 72 hours postinjury. *P<0.05; **P<0.01 versus control antibody; error
bars = SEM. (B) Kidneys were harvested at 24 and 72 hours postclamp from the study in A. Histopathologic examination
of hematoxylin and eosin–stained kidney sections utilized several morphologic features to generate a composite lesion
score (see Concise Methods for details). Rats treated with αvβ5 antibody had a significantly lower score at 72 hours post-
IRI. *P<0.05 compared with control antibody.
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Figure 3.
αvβ5 inhibition decreases ischemia-induced apoptosis. Kidneys were harvested at 24 and 72 hours postclamp after a single
dose (3 mg/kg) of αvβ5 antibody 6 hours preclamp. Activated capsase-3 was used as a measure of apoptosis in post-IRI
kidney sections. The degree of caspase-3 immunoreactivity was quantified and calculated as a percent area of medulla.
Rats treated with αvβ5 antibody had significantly reduced apoptosis in the renal medulla at 24 hours postinjury. *P<0.05
compared with control antibody.
Inhibition of αvβ5 Integrin Attenuates Vascular Permeability and Protect... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461783/?report=printable
16 of 23 2/15/2019, 7:27 AM
Table 1.
Selected pathways regulated by αvβ5 inhibition
Function Annotation P Value Z-Score Predicted Activation
Angiogenesis 3.11E-05 2.574 Increased
Migration of endothelial cells 1.66E-04 2.335 Increased
Differentiation of endothelial cells 3.34E-05 1.893 Increased
Kidney development 9.52E-03 1.676 Increased
Proliferation of kidney cells 2.57E-02 1.580 Increased
Apoptosis of renal epithelial cells 1.10E-03 −2.011 Decreased
Failure of kidney 7.16E-06 −2.126 Decreased
Adhesion of immune cells 2.10E-04 −2.298 Decreased
Atrophy of renal tubule 1.62E-04 −2.414 Decreased
Fibrosis 2.23E-06 −2.498 Decreased
Recruitment of immune cells 1.12E-05 −2.555 Decreased
Hydronephrosis 6.94E-07 −2.600 Decreased
Ingenuity Pathway Analysis was performed on transcripts differentially expressed at 24 and 72 hours post-IRI with
αvβ5 antibody compared with control antibody (fold change >1.5; false discovery rate <0.05). Ingenuity Pathway
Analysis Z-scores >1.5 or <−1.5 predicted increased or decreased activation of biologic functions with αvβ5 inhibition.
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Figure 4.
Profiling of kidney reveals previously identified genes in rodent and human AKI are altered with αvβ5 inhibition. Heat
map depicts transcripts differentially expressed at 24 or 72 hours post-IRI with αvβ5 antibody treatment compared with
control antibody treatment. Table includes genes previously identified as altered in rodent IR models and in human AKI
that were oppositely regulated with αvβ5 antibody treatment.
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Figure 5.
αvβ5 inhibition reduces vascular leak after injury. (A) Texas Red-conjugated albumin and a 150 kD fluorescein-dextran
were intravenously coinjected into rats at 24 hours post-ischemia to evaluate microvascular permeability after injury.
Intravital imaging of the cortex revealed leakage of both the albumin and the high molecular weight dextran from the renal
microvasculature in the control antibody-treated animals (A and B), and this leak was substantially reduced in the αvβ5
antibody-treated animals (C and D). The images were scored for degree of extravasation and the average leak scores for
albumin (E) and the 150 kD dextran (F) were calculated. *P<0.05; **P<0.01 versus control antibody; error bars = SEM;
image dimensions = 212×212 μm.
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Figure 6.
Characterization of αvβ5 integrin expression in the kidney. Frozen sections of mouse kidney were stained for αvβ5 (red),
CD31 (green), and PDGFRβ (white) with nuclei in blue. Representative images (63× magnification) from the glomerulus,
cortex, medulla as well as an artery are shown. αvβ5 is expressed in podocytes, mesangial, epithelial, and perivascular
cells of the kidney and within interstitial cells, and appears to be present within PDGFRβ-positive cells, but not in CD31-
positive endothelial cells.
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Figure 7.
αvβ5 regulates vascular permeability in a pericyte-dependent manner. (A) Human kidney endothelial cells were seeded
into a three-dimensional microfluidic device and allowed to form a tube in the presence of flow. Cells were treated with
control or αvβ5 antibody 1 hour before challenge with thrombin (3 U/ml). 70 kD Texas Red albumin was perfused into the
vessel and the diffusion was measured by confocal microscopy to calculate the diffusive permeability coefficient (P ). No
significant difference was observed with αvβ5 antibody with endothelial cells alone (n=6). (B) All conditions are the same
as described above except human kidney pericytes are first seeded into the microfluidics device, followed by seeding with
the endothelial cells. In this condition, the αvβ5 antibody significantly inhibited the thrombin-induced vascular
permeability. *P<0.05 versus thrombin + control antibody; error bars = SEM.
d
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Figure 8.
αvβ5 regulates pericyte adhesion and migration on vitronectin. Human kidney pericytes were seeded on plates coated with
collagen or vitronectin. (A) Fluorescently labeled cells are seeded in the presence of the αvβ5 antibody, an αvβ3 antibody,
or a control antibody and were counted after washing the adherent cells. The αvβ5 antibody significantly reduced adhesion
of cells on vitronectin compared with control antibody treatment. ***P<0.001 versus control antibody; error bars = SEM.
(B) Cells were treated with antibody 1 hour before scratch wound, and images were taken every 2 hours for 2 days and
wound confluence was calculated. The αvβ3 antibody had no significant effect on migration, the JNK inhibitor SP600125
(included as a positive control) inhibited migration on both substrates and the αvβ5 antibody significantly inhibited
migration of pericytes on vitronectin. *P<0.05 versus control antibody.
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Figure 9.
Treatment with αvβ5 antibody after ischemia provides protection from injury. (A) Rats were treated with a single dose (3
mg/kg) of αvβ5 antibody 8 hours postclamp release. This single dose was effective in attenuating ischemia-induced serum
creatinine increases at 48 hours postinjury. *P<0.05 versus control antibody; error bars = SEM. (B) Kidneys were
harvested at 72 hours postclamp from the study in A for quantitative PCR analysis. At 8 hours postclamp, treatment
significantly reduced the expression of two biomarkers induced by injury (havcr1, lcn2) and increased the expression of
two biomarkers diminished by injury (umod, egf). *P<0.05; **P<0.01 versus control antibody; error bars = SEM.
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